Deutsch English Français

Contact

EP2101823

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2101823

EP2101823 - RNA-CODED ANTIBODY [Right-click to bookmark this link]
Status	Patent revoked Status updated on 20.10.2023 Database last updated on 06.07.2024
Former	The patent has been granted Status updated on 26.09.2019
Most recent event Tooltip	02.02.2024	Lapse of the patent in a contracting state New state(s): DK	published on 06.03.2024 [2024/10]
Applicant(s)	For all designated states CureVac SE Friedrich-Miescher-Straße 15 72076 Tübingen / DE
	[2023/01]
Former [2021/10]	For all designated states CureVac AG Friedrich-Miescher-Straße 15 72076 Tübingen / DE
Former [2015/49]	For all designated states CureVac AG Paul-Ehrlich-Str. 15 72076 Tübingen / DE
Former [2009/39]	For all designated states Curevac GmbH Paul-Ehrlich-Str. 15 72076 Tübingen / DE
Inventor(s)	01 / HOERR, Ingmar Charlottenstrasse 16 72070 Tübingen / DE
	02 / PROBST, Jochen In den Kirchhofländern 19 72649 Wolfschlugen / DE
	03 / PASCOLO, Steve Kanzleistrasse 231 8004 Zürich / CH
	[2010/16]
Former [2009/39]	01 / HOERR, Ingmar Charlottenstrasse 16 72070 Tübingen / DE
	02 / PROBST, Jochen In den Kirchhofländern 19 72649 Wolfschlugen / DE
Representative(s)	Graf von Stosch, Andreas, et al Graf von Stosch Patentanwaltsgesellschaft mbH Prinzregentenstraße 22 80538 München / DE
	[2016/47]
Former [2009/39]	Graf von Stosch, Andreas, et al Graf von Stosch Patentanwaltsgesellschaft mbH Prinzregentenstrasse 22 80538 München / DE
Application number, filing date	08701020.3	08.01.2008
	[2009/39]
	WO2008EP00081
Priority number, date	DE20071001370	09.01.2007 Original published format: DE102007001370
	[2009/39]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2008083949
	Date:	17.07.2008
	Language:	EN
	[2008/29]
	Type:	A2 Application without search report
	No.:	EP2101823
	Date:	23.09.2009
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 17.07.2008 takes the place of the publication of the European patent application.
	[2009/39]
	Type:	B1 Patent specification
	No.:	EP2101823
	Date:	23.11.2016
	Language:	EN
	[2016/47]
Search report(s)	International search report - published on:	EP	25.09.2008
Classification	IPC:	A61K48/00, C12N15/13, C12N15/85, C07K16/28, C07K16/32, A61K39/395	[2009/39]
	CPC:	C07K16/2863 (EP,US); C07K16/1027 (US); A61K39/395 (US); A61K39/39558 (US); A61K39/40 (US); A61K39/42 (US); (+) A61K48/005 (US); A61K48/0066 (US); A61K48/0075 (US); A61K9/0019 (US); A61P25/00 (EP); A61P31/00 (EP); A61P33/00 (EP); A61P35/00 (EP); A61P37/00 (EP); A61P37/04 (EP); A61P9/00 (EP); C07K16/1018 (US); C07K16/2803 (US); C07K16/2887 (EP,US); C07K16/30 (US); C07K16/3046 (US); C07K16/3061 (US); C07K16/32 (EP,US); A61K2039/505 (US); A61K2039/51 (EP,US); A61K2039/53 (EP,US); A61K48/00 (US); C07K2317/21 (US); C07K2317/24 (EP,US); C07K2317/51 (US); C07K2317/515 (US); C07K2317/52 (US); C07K2317/54 (US); C07K2317/55 (US); C07K2317/56 (EP,US); C07K2317/622 (US); C07K2317/76 (US); C07K2317/77 (US); C07K2317/92 (US); C07K2317/94 (US); Y02A50/30 (EP,US) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2016/47]
Former [2009/39]	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR
Title	German:	RNA-KODIERTER ANTIKÖRPER	[2009/39]
	English:	RNA-CODED ANTIBODY	[2009/39]
	French:	ANTICORPS CODE PAR UN ARN	[2009/39]
Entry into regional phase	08.04.2009	National basic fee paid
	08.04.2009	Designation fee(s) paid
	08.04.2009	Examination fee paid
Examination procedure	08.04.2009	Amendment by applicant (claims and/or description)
	08.04.2009	Examination requested [2009/39]
	09.11.2009	Despatch of a communication from the examining division (Time limit: M04)
	23.12.2009	Reply to a communication from the examining division
	16.02.2010	Despatch of a communication from the examining division (Time limit: M04)
	02.06.2010	Reply to a communication from the examining division
	02.09.2010	Despatch of a communication from the examining division (Time limit: M06)
	15.03.2011	Application deemed to be withdrawn, date of legal effect [2011/36]
	20.06.2012	Reply to a communication from the examining division
	deleted	Deletion: Application deemed to be withdrawn, date of legal effect [2014/08]
	19.12.2014	Despatch of a communication from the examining division (Time limit: M06)
	05.10.2015	Reply to a communication from the examining division
	11.03.2016	Despatch of a communication from the examining division (Time limit: M04)
	17.05.2016	Reply to a communication from the examining division
	04.07.2016	Communication of intention to grant the patent
	09.08.2016	Fee for grant paid
	09.08.2016	Fee for publishing/printing paid
	09.08.2016	Receipt of the translation of the claim(s)
	11.08.2016	Observations by third parties
Divisional application(s)	EP16001146.6 / EP3115064
	EP16001778.6 / EP3118224
	EP17198401.6 / EP3329941
	EP19192410.9 / EP3636669
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 09.11.2009
Opposition(s)	Opponent(s)	01 11.08.2017 21.08.2017 ADMISSIBLE eTheRNA Immunotherapies NV Galileilaan 19 2845 Niel / BE Opponent's representative Arnold & Siedsma, et al, et al Bezuidenhoutseweg 57 2594 AC The Hague / NL
		02 17.08.2017 26.03.2019 WITHDRAWN F. Hoffmann-La Roche AG Grenzacherstr. 124 4070 Basel / CH Opponent's representative D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB
		03 23.08.2017 30.08.2017 ADMISSIBLE Weinzierl, Gerhard c/o Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE Opponent's representative Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE
		04 23.08.2017 30.08.2017 ADMISSIBLE Strawman Limited Orchard Lea Horns Lane Combe, Witney Oxfordshire OX29 8NH / GB Opponent's representative Himmelsbach, Mathias Frohwitter Patent- und Rechtsanwälte Possartstraße 20 81679 München / DE
		05 23.08.2017 30.08.2017 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Wilding, James Roger, et al, et al Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
		06 23.08.2017 30.08.2017 ADMISSIBLE Moderna Therapeutics, Inc. 200 Technology Square, 3rd Floor Cambridge, MA 02139 / US Opponent's representative EIP Fairfax House 15 Fulwood Place London WC1V 6HU / GB
		[N/P]
	Former [2023/03]
	Opponent(s)	01 11.08.2017 21.08.2017 ADMISSIBLE eTheRNA Immunotherapies NV Galileilaan 19 2845 Niel / BE Opponent's representative Arnold & Siedsma, et al, et al Bezuidenhoutseweg 57 2594 AC The Hague / NL
		02 17.08.2017 26.03.2019 WITHDRAWN F. Hoffmann-La Roche AG Grenzacherstr. 124 4070 Basel / CH Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 23.08.2017 30.08.2017 ADMISSIBLE Weinzierl, Gerhard c/o Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE Opponent's representative Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE
		04 23.08.2017 30.08.2017 ADMISSIBLE Strawman Limited Orchard Lea Horns Lane Combe, Witney Oxfordshire OX29 8NH / GB Opponent's representative Himmelsbach, Mathias Frohwitter Patent- und Rechtsanwälte Possartstraße 20 81679 München / DE
		05 23.08.2017 30.08.2017 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Wilding, James Roger, et al, et al Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
		06 23.08.2017 30.08.2017 ADMISSIBLE Moderna Therapeutics, Inc. 200 Technology Square, 3rd Floor Cambridge, MA 02139 / US Opponent's representative EIP Fairfax House 15 Fulwood Place London WC1V 6HU / GB
	Former [2023/01]
	Opponent(s)	01 11.08.2017 21.08.2017 ADMISSIBLE eTheRNA Immunotherapies NV Galileilaan 19 2845 Niel / BE Opponent's representative Arnold & Siedsma, et al, et al Bezuidenhoutseweg 57 2594 AC The Hague / NL
		02 17.08.2017 26.03.2019 WITHDRAWN F. Hoffmann-La Roche AG Grenzacherstr. 124 4070 Basel / CH Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 23.08.2017 30.08.2017 ADMISSIBLE Weinzierl, Gerhard c/o Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE Opponent's representative Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE
		04 23.08.2017 30.08.2017 ADMISSIBLE Strawman Limited Orchard Lea Horns Lane Combe, Witney Oxfordshire OX29 8NH / GB Opponent's representative Himmelsbach, Mathias Frohwitter Patent- und Rechtsanwälte Possartstraße 20 81679 München / DE
		05 23.08.2017 30.08.2017 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Wilding, James Roger, et al, et al Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
		06 23.08.2017 30.08.2017 ADMISSIBLE Moderna Therapeutics, Inc. 200 Technology Square, 3rd Floor Cambridge, MA 02139 / US Opponent's representative Rai, Monika EIP Europe LLP Fairfax House 15 Fulwood Place London WC1V 6HU / GB
	Former [2021/12]
	Opponent(s)	01 11.08.2017 21.08.2017 ADMISSIBLE eTheRNA Immunotherapies NV Galileilaan 19 2845 Niel / BE Opponent's representative Arnold & Siedsma, et al, et al Bezuidenhoutseweg 57 2594 AC The Hague / NL
		02 17.08.2017 26.03.2019 WITHDRAWN F. Hoffmann-La Roche AG Grenzacherstr. 124 4070 Basel / CH Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 23.08.2017 30.08.2017 ADMISSIBLE Weinzierl, Gerhard c/o Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE Opponent's representative Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE
		04 23.08.2017 30.08.2017 ADMISSIBLE Strawman Limited Orchard Lea Horns Lane Combe, Witney Oxfordshire OX29 8NH / GB Opponent's representative Himmelsbach, Mathias Frohwitter Patent- und Rechtsanwälte Possartstraße 20 81679 München / DE
		05 23.08.2017 30.08.2017 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Wilding, James Roger, et al, et al Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
		06 23.08.2017 30.08.2017 ADMISSIBLE Moderna Therapeutics, Inc. 200 Technology Square, 3rd Floor Cambridge, MA 02139 / US Opponent's representative Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
	Former [2021/10]
	Opponent(s)	01 11.08.2017 21.08.2017 ADMISSIBLE eTheRNA Immunotherapies NV Galileilaan 19 2845 Niel / BE Opponent's representative LC Patents, et al, et al Kempische Steenweg 542A 3500 Hasselt / BE
		02 17.08.2017 26.03.2019 WITHDRAWN F. Hoffmann-La Roche AG Grenzacherstr. 124 4070 Basel / CH Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 23.08.2017 30.08.2017 ADMISSIBLE Weinzierl, Gerhard c/o Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE Opponent's representative Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE
		04 23.08.2017 30.08.2017 ADMISSIBLE Strawman Limited Orchard Lea Horns Lane Combe, Witney Oxfordshire OX29 8NH / GB Opponent's representative Himmelsbach, Mathias Frohwitter Patent- und Rechtsanwälte Possartstraße 20 81679 München / DE
		05 23.08.2017 30.08.2017 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Wilding, James Roger, et al, et al Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
		06 23.08.2017 30.08.2017 ADMISSIBLE Moderna Therapeutics, Inc. 200 Technology Square, 3rd Floor Cambridge, MA 02139 / US Opponent's representative Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
	Former [2020/21]
	Opponent(s)	01 11.08.2017 21.08.2017 ADMISSIBLE eTheRNA Immunotherapies NV Galileilaan 19 2845 Niel / BE Opponent's representative LC Patents, et al, et al Kempische Steenweg 542A 3500 Hasselt / BE
		02 17.08.2017 26.03.2019 WITHDRAWN F. Hoffmann-La Roche AG Grenzacherstr. 124 4070 Basel / CH Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 23.08.2017 30.08.2017 ADMISSIBLE Weinzierl, Gerhard c/o Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE Opponent's representative Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE
		04 23.08.2017 30.08.2017 ADMISSIBLE Strawman Limited Orchard Lea Horns Lane Combe, Witney Oxfordshire OX29 8NH / GB Opponent's representative Himmelsbach, Mathias Frohwitter Patent- und Rechtsanwälte Possartstraße 20 81679 München / DE
		05 23.08.2017 30.08.2017 ADMISSIBLE Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Wilding, James Roger, et al, et al Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
		06 23.08.2017 30.08.2017 ADMISSIBLE Moderna Therapeutics, Inc. 200 Technology Square, 3rd Floor Cambridge, MA 02139 / US Opponent's representative Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
	Former [2019/21]
	Opponent(s)	01 11.08.2017 21.08.2017 ADMISSIBLE eTheRNA Immunotherapies NV Galileilaan 19 2845 Niel / BE Opponent's representative LC Patents, et al, et al Kempische Steenweg 542A 3500 Hasselt / BE
		02 17.08.2017 26.03.2019 WITHDRAWN F. Hoffmann-La Roche AG Grenzacherstr. 124 4070 Basel / CH Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 23.08.2017 30.08.2017 ADMISSIBLE Weinzierl, Gerhard c/o Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE Opponent's representative Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE
		04 23.08.2017 30.08.2017 ADMISSIBLE Strawman Limited Orchard Lea Horns Lane Combe, Witney Oxfordshire OX29 8NH / GB Opponent's representative Himmelsbach, Mathias Frohwitter Patent- und Rechtsanwälte Possartstraße 20 81679 München / DE
		05 23.08.2017 30.08.2017 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Wilding, James Roger, et al, et al Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
		06 23.08.2017 30.08.2017 ADMISSIBLE Moderna Therapeutics, Inc. 200 Technology Square, 3rd Floor Cambridge, MA 02139 / US Opponent's representative Rai, Monika Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
	Former [2019/18]
	Opponent(s)	01 11.08.2017 21.08.2017 ADMISSIBLE eTheRNA Immunotherapies NV Galileilaan 19 2845 Niel / BE Opponent's representative LC Patents, et al, et al Kempische Steenweg 542A 3500 Hasselt / BE
		02 17.08.2017 26.03.2019 WITHDRAWN F. Hoffmann-La Roche AG Grenzacherstr. 124 4070 Basel / CH Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 23.08.2017 30.08.2017 ADMISSIBLE Weinzierl, Gerhard c/o Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE Opponent's representative Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE
		04 23.08.2017 30.08.2017 ADMISSIBLE Strawman Limited Orchard Lea Horns Lane Combe, Witney Oxfordshire OX29 8NH / GB Opponent's representative Himmelsbach, Mathias Frohwitter Patent- und Rechtsanwälte Possartstraße 20 81679 München / DE
		05 23.08.2017 30.08.2017 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Garner, Stephen, et al, et al Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
		06 23.08.2017 30.08.2017 ADMISSIBLE Moderna Therapeutics, Inc. 200 Technology Square, 3rd Floor Cambridge, MA 02139 / US Opponent's representative Rai, Monika Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
	Former [2017/40]
	Opponent(s)	01 11.08.2017 21.08.2017 ADMISSIBLE eTheRNA Immunotherapies NV Galileilaan 19 2845 Niel / BE Opponent's representative LC Patents, et al, et al Kempische Steenweg 542A 3500 Hasselt / BE
		02 17.08.2017 22.08.2017 ADMISSIBLE F. Hoffmann-La Roche AG Grenzacherstr. 124 4070 Basel / CH Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 23.08.2017 30.08.2017 ADMISSIBLE Weinzierl, Gerhard c/o Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE Opponent's representative Schiweck, Weinzierl & Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE
		04 23.08.2017 30.08.2017 ADMISSIBLE Strawman Limited Orchard Lea Horns Lane Combe, Witney Oxfordshire OX29 8NH / GB Opponent's representative Himmelsbach, Mathias Frohwitter Patent- und Rechtsanwälte Possartstraße 20 81679 München / DE
		05 23.08.2017 30.08.2017 ADMISSIBLE Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Garner, Stephen, et al, et al Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
		06 23.08.2017 30.08.2017 ADMISSIBLE Moderna Therapeutics, Inc. 200 Technology Square, 3rd Floor Cambridge, MA 02139 / US Opponent's representative Rai, Monika Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
	Former [2017/39]
	Opponent(s)	01 11.08.2017 21.08.2017 ADMISSIBLE eTheRNA Immunotherapies NV Galileilaan 19 2845 Niel / BE Opponent's representative LC Patents, et al, et al Kempische Steenweg 542A 3500 Hasselt / BE
		02 17.08.2017 22.08.2017 ADMISSIBLE F. Hoffmann-La Roche AG Grenzacherstr. 124 4070 Basel / CH Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		03 23.08.2017 Weinzierl, Gerhard Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE Opponent's representative Schiweck, Weinzierl & Koch Patentanwälte Partnerschaft mbB Landsberger Straße 98 80339 München / DE
		04 23.08.2017 ADMISSIBLE Strawman Limited Orchard Lea Horns Lane Combe, Witney Oxfordshire OX29 8NH / GB Opponent's representative Himmelsbach, Mathias Frohwitter Patent- und Rechtsanwälte Possartstraße 20 81679 München / DE
		05 23.08.2017 Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Garner, Stephen, et al, et al Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
		06 23.08.2017 Moderna Therapeutics, Inc. 200 Technology Square, 3rd Floor Cambridge, MA 02139 / US Opponent's representative Rai, Monika Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
	Former [2017/38]
	Opponent(s)	01 11.08.2017 ADMISSIBLE eTheRNA Immunotherapies NV Galileilaan 19 2845 Niel / BE Opponent's representative LC Patents, et al, et al Kempische Steenweg 542A 3500 Hasselt / BE
	29.09.2017	Invitation to proprietor to file observations on the notice of opposition
	09.05.2018	Reply of patent proprietor to notice(s) of opposition
	25.06.2019	Date of oral proceedings
	27.09.2019	Despatch of minutes of oral proceedings
	27.09.2019	Despatch of communication that the patent will be revoked
	09.10.2023	Legal effect of revocation of patent [2023/47]
Appeal following opposition	15.11.2019	Appeal received No. T3147/19
	31.12.2019	Statement of grounds filed
	09.10.2023	Result of appeal procedure: appeal of the proprietor withdrawn
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	05.10.2015	Request for further processing filed
	05.10.2015	Full payment received (date of receipt of payment) Request granted
	16.10.2015	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the examination report
	29.06.2011	Request for further processing filed
	29.06.2011	Full payment received (date of receipt of payment) Request granted
	17.12.2013	Decision despatched
Request for re-establishment of rights:	20.06.2012	Date of receipt
Fees paid	Renewal fee
	16.11.2009	Renewal fee patent year 03
	22.11.2010	Renewal fee patent year 04
	31.01.2011	Renewal fee patent year 05
	23.01.2013	Renewal fee patent year 06
	30.12.2013	Renewal fee patent year 07
	17.11.2014	Renewal fee patent year 08
	14.12.2015	Renewal fee patent year 09
	Penalty fee
	Additional fee for renewal fee
	31.01.2012	05 M06 Fee paid on 20.06.2012
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	08.01.2008
	BG	23.11.2016
	CY	23.11.2016
	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	MC	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	SI	23.11.2016
	SK	23.11.2016
	TR	23.11.2016
	LU	08.01.2017
	MT	08.01.2017
	NO	23.02.2017
	GR	24.02.2017
	IS	23.03.2017
	PT	23.03.2017
	SE	09.01.2023
	DK	31.01.2023
	NL	01.02.2023
	[2024/10]
Former [2023/48]	HU	08.01.2008
	BG	23.11.2016
	CY	23.11.2016
	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	MC	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	SI	23.11.2016
	SK	23.11.2016
	TR	23.11.2016
	LU	08.01.2017
	MT	08.01.2017
	NO	23.02.2017
	GR	24.02.2017
	IS	23.03.2017
	PT	23.03.2017
	SE	09.01.2023
	NL	01.02.2023
Former [2020/33]	HU	08.01.2008
	BG	23.11.2016
	CY	23.11.2016
	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	MC	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	SI	23.11.2016
	SK	23.11.2016
	TR	23.11.2016
	LU	08.01.2017
	MT	08.01.2017
	NO	23.02.2017
	GR	24.02.2017
	IS	23.03.2017
	PT	23.03.2017
Former [2020/15]	HU	08.01.2008
	BG	23.11.2016
	CY	23.11.2016
	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	MC	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	SI	23.11.2016
	SK	23.11.2016
	TR	23.11.2016
	LU	08.01.2017
	MT	08.01.2017
	NO	23.02.2017
	GR	24.02.2017
	PT	23.03.2017
Former [2019/46]	HU	08.01.2008
	BG	23.11.2016
	CY	23.11.2016
	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	MC	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	SI	23.11.2016
	SK	23.11.2016
	LU	08.01.2017
	MT	08.01.2017
	NO	23.02.2017
	GR	24.02.2017
	PT	23.03.2017
Former [2019/41]	HU	08.01.2008
	BG	23.11.2016
	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	MC	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	SI	23.11.2016
	SK	23.11.2016
	LU	08.01.2017
	MT	08.01.2017
	NO	23.02.2017
	GR	24.02.2017
	PT	23.03.2017
Former [2019/39]	HU	08.01.2008
	BG	23.11.2016
	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	MC	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	SK	23.11.2016
	LU	08.01.2017
	MT	08.01.2017
	NO	23.02.2017
	GR	24.02.2017
	PT	23.03.2017
Former [2019/31]	HU	08.01.2008
	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	MC	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	SK	23.11.2016
	LU	08.01.2017
	MT	08.01.2017
	NO	23.02.2017
	GR	24.02.2017
	PT	23.03.2017
Former [2018/43]	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	MC	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	SK	23.11.2016
	LU	08.01.2017
	MT	08.01.2017
	NO	23.02.2017
	GR	24.02.2017
	PT	23.03.2017
Former [2018/02]	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	MC	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	SK	23.11.2016
	LU	08.01.2017
	NO	23.02.2017
	GR	24.02.2017
	PT	23.03.2017
Former [2017/42]	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	MC	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	SK	23.11.2016
	NO	23.02.2017
	GR	24.02.2017
	PT	23.03.2017
Former [2017/37]	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	SK	23.11.2016
	NO	23.02.2017
	GR	24.02.2017
	PT	23.03.2017
Former [2017/35]	CZ	23.11.2016
	EE	23.11.2016
	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	PL	23.11.2016
	RO	23.11.2016
	NO	23.02.2017
	GR	24.02.2017
	PT	23.03.2017
Former [2017/26]	FI	23.11.2016
	HR	23.11.2016
	LT	23.11.2016
	LV	23.11.2016
	PL	23.11.2016
	NO	23.02.2017
	GR	24.02.2017
	PT	23.03.2017
Former [2017/12]	LV	23.11.2016
Cited in	International search	[Y]US5736137 (ANDERSON DARRELL R [US], et al) [Y] 21,22,27 * figures 4,5 *;
		[Y]US2003153735 (BREECE TIMOTHY N [US], et al) [Y] 25-27 * figures 1A,1B *;
		[Y]WO2004085474 (IMCLONE SYSTEMS INC [US], et al) [Y] 23,24,27 * figures 1,2 *;
		[Y]EP1604688 (CUREVAC GMBH [DE]) [Y] 9,22,24,26,27 * examples 1-4 *;
		[XY] - HU ET AL, "Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, (20060501), vol. 47, no. 1, ISSN 1046-5928, pages 249 - 257, XP005392638 [X] 1-8,10-20 * page 252 * [Y] 9,21-27 DOI: http://dx.doi.org/10.1016/j.pep.2005.11.014
		[XY] - MAYFIELD STEPHEN P ET AL, "Expression and assembly of a fully active antibody in algae", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, (20030121), vol. 100, no. 2, ISSN 0027-8424, pages 438 - 442, XP002440629 [X] 1-8,10-20 * page 439 - page 440 * [Y] 9,21-27 DOI: http://dx.doi.org/10.1073/pnas.0237108100
		[XY] - VAQUERO C ET AL, "Transient expression of a tumor-specific single-chain fragment and a chimeric antibody in tobacco leaves", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, (19990928), vol. 96, no. 20, ISSN 0027-8424, pages 11128 - 11133, XP002454738 [X] 1-8,10-20 * page 11128 - page 11129 * * page 11131, column LEFT * [Y] 9,21-27 DOI: http://dx.doi.org/10.1073/pnas.96.20.11128
		[Y] - KUDLA GRZEGORZ ET AL, "High guanine and cytosine content increases mRNA levels in mammalian cells.", PLOS BIOLOGY JUN 2006, (200606), vol. 4, no. 6, ISSN 1545-7885, page e180, XP002484439 [Y] 9,22,24,26,27 * the whole document * DOI: http://dx.doi.org/10.1371/journal.pbio.0040180
		[Y] - GRAF M ET AL, "CODON-OPTIMIZED GENES THAT ENABLE INCREASED HETEROLOGOUS EXPRESSION IN MAMMALIAN CELLS AND ELICIT EFFICIENT IMMUNE RESPONSES IN MICE AFTER VACCINATION OF NAKED DNA", METHODS IN MOLECULAR MEDICINE, HUMANA PRESS, TOTOWA, NJ, US, (20040101), vol. 94, ISSN 1543-1894, pages 197 - 210, XP001246616 [Y] 22,24,26,27 * the whole document *
		[XY] - KHARE P D ET AL, "TUMOR GROWTH SUPPRESSION BY A RETROVIRAL VECTOR DISPLAYING SCFV ANTIBODY TO CEA AND CARRYING THE INOS GENE", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS, (20020101), vol. 22, ISSN 0250-7005, pages 2443 - 2446, XP008054734 [X] 1-8,10-31 * the whole document * [Y] 9
		[Y] - IVANOVSKA ET AL, "Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD21-specific antibody fragment induces long-lasting IgM and CTL responses to influenza virus", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, (20060310), vol. 24, no. 11, ISSN 0264-410X, pages 1830 - 1837, XP005294681 [Y] 28-32 * the whole document * DOI: http://dx.doi.org/10.1016/j.vaccine.2005.10.029
		[X] - OHASHI ET AL, "Efficient protein selection based on ribosome display system with purified components", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, (20061130), vol. 352, no. 1, ISSN 0006-291X, pages 270 - 276, XP005725399 [X] 1-7,15-20,35-37 * the whole document * DOI: http://dx.doi.org/10.1016/j.bbrc.2006.11.017
		[Y] - ZEYTIN H E ET AL, "CONSTRUCTION AND CHARACTERIZATION OF DNA VACCINES ENCODING THE SINGLE-CHAIN VARIABLE FRAGMENT OF THE ANTI-IDIOTYPE ANTIBODY 1A7 MIMICKING THE TUMOR-ASSOCIATED ANTIGEN DISIALOGANGLIOSIDE GD2", CANCER GENE THERAPY, NORWALK, CT, US, (20001101), vol. 7, no. 11, ISSN 0929-1903, pages 1426 - 1436, XP001145646 [Y] 28-32 * the whole document * DOI: http://dx.doi.org/10.1038/sj.cgt.7700240
		[Y] - CARRALOT J-P ET AL, "Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, HEIDELBERG, DE, (20040901), vol. 61, no. 18, ISSN 1420-682X, pages 2418 - 2424, XP002355208 [Y] 28-32 * the whole document * DOI: http://dx.doi.org/10.1007/s00018-004-4255-0
		[A] - CREE BRUCE ET AL, "Tolerability and effects of Rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS)", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, (20040401), vol. 62, no. 7, Suppl. 5, ISSN 0028-3878, page A492, XP009080814 [A] 33,34 * the whole document *
		[Y] - KOLB ET AL, "A virus-neutralising antibody is not cytotoxic in vitro", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, (20060201), vol. 43, no. 6, ISSN 0161-5890, pages 677 - 689, XP005211235 [Y] 21,23,25 * page 681, column LEFT * DOI: http://dx.doi.org/10.1016/j.molimm.2005.04.008
		[T] - BAKKER J M ET AL, "Therapeutic Antibody Gene Transfer: An Active Approach to Passive Immunity", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, (20040901), vol. 10, no. 3, ISSN 1525-0016, pages 411 - 416, XP004660582 [T] 28-34 * page 413 - page 414 * DOI: http://dx.doi.org/10.1016/j.ymthe.2004.06.865
	Examination	- KITAGUCHI KOHJI ET AL, "Immune deficiency enhances expression of recombinant human antibody in mice after nonviral in vivo gene transfer.", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE OCT 2005, (200510), vol. 16, no. 4, ISSN 1107-3756, pages 683 - 688, XP008118466
		- PASCOLO STEVE, "Vaccination with messenger RNA", METHODS IN MOLECULAR MEDICINE HUMANA PRESS INC, 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SERIES : METHODS IN MOLECULAR MEDICINE (ISSN 1543-1894(PRINT)), (2006), pages 23 - 40, XP009117840
		- BANDBON BALENGA ET AL, "Bicistronic expression plasmid encoding allergen and anti-IgE single chain variable fragment antibody as a novel DNA vaccine for allergy therapy and prevention", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, (20060101), vol. 67, no. 1, ISSN 0306-9877, pages 71 - 74, XP005397016 DOI: http://dx.doi.org/10.1016/j.mehy.2005.12.044
		- HOERR INGMAR, "Stabilized messenger RNA (RNActive (TM)) as a tool for innovative gene delivery", TISSUE ENGINEERING, & 2ND INTERNATIONAL CONGRESS ON REGENERATIVE BIOLOGY/2ND INTERNATIONAL CONGRESS ON BIO-NANO-INTERFACE; STUTTGART, GERMANY; OCTOBER 09 -11, 2006, (20070401), vol. 13, no. 4, pages 886 - 887, XP009125215
		- "Non-Viral DNA and mRNA Gene Delivery to the CNS Pre-Operatively for Neuroprotection and Following Neurotrauma", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA, US, (20040501), vol. 9, ISSN 1525-0016, page 258, XP004635047
		- FINGER CARSTEN ET AL, "Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.", CANCER GENE THERAPY MAY 2005, (200505), vol. 12, no. 5, doi:doi:10.1038/sj.cgt.7700805, ISSN 0929-1903, pages 464 - 474, XP055039486 DOI: http://dx.doi.org/10.1038/sj.cgt.7700805
		- PAUL R HESS ET AL, "Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20060601), vol. 55, no. 6, doi:10.1007/S00262-005-0064-Z, ISSN 1432-0851, pages 672 - 683, XP019333249 DOI: http://dx.doi.org/10.1007/s00262-005-0064-z
		- PROBST J ET AL, "Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent.", GENE THERAPY AUG 2007, (200708), vol. 14, no. 15, doi:doi:10.1038/SJ.GT.3302964, ISSN 0969-7128, pages 1175 - 1180, XP002679377 DOI: http://dx.doi.org/10.1038/SJ.GT.3302964
		- FUKUDA ISAO; KOJOH KANEHISA; TABATA NORIKO; DOI NOBUHIDE; TAKASHIMA HIDEAKI; MIYAMOTO-SATO ETSUKO; YANAGAWA HIROSHI, "In vitro evolution of single-chain antibodies using mRNA display.", NUCLEIC ACIDS RESEARCH, (20060929), vol. 34, no. 19, doi:doi:10.1093/NAR/GKL618, page E127, XP002639193 DOI: http://dx.doi.org/10.1093/NAR/GKL618
		- LESAFFRE BRIGITTE; JOLIOT ALAIN; PROCHIANTZ ALAIN; VOLOVITCH MICHEL, "Direct non-cell autonomous Pax6 activity regulates eye development in the zebrafish", NEURAL DEVELOPMENT, (20070117), vol. 2, page 2, XP021026216 DOI: http://dx.doi.org/10.1186/1749-8104-2-2
	Opposition	WO9011092
		WO9914346
		WO9957275
		EP1084246
		US2003083272
		US2003099646
		US2004132683
		US2004142885
		US2005032730
		US2005059624
		EP1604688
		WO2006000001
		EP1619254
		WO2006024518
		US2006188490
		US2008025944
		US2008171711
		US2008267873
		WO2010037408
		US2010189729
		US2011143397
		EP2578685
		US2016166692
		US2016185840
		WO9312814
		US2003175239
		WO2006037807
		WO2006116458
		WO2006122828
		US5580859
		EP1083232
		US6214804
		WO2008052770
		US5736137
		WO03059381
		US2003153735
		WO2004085474
		WO2010037539
		WO2015062738
		- PARDI et al., "Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge", Nature Communications, (20170302), vol. 8, pages 1 - 8, XP055410616 DOI: http://dx.doi.org/10.1038/ncomms14630
		- STADLER et al., "Elimination of large tumors in mice by mRNA-encoded bispecific antibodies", Nature Medicine, (20170700), vol. 23, no. 7, pages 815 - 817, XP055410619 DOI: http://dx.doi.org/10.1038/nm.4356
		- PEREZ et al., "Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation", Genetic Vaccines and Therapy, (20040323), vol. 2, no. 2, pages 1 - 5, XP055410620
		- BIOCCA et al., "Expression and targeting of intracellular antibodies in mammalian cells", The Embo Journal, (19900000), vol. 9, no. 1, pages 101 - 108, XP002912873
		- HOERR et al., "In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies", European Journal of Immunology, (20000100), vol. 30, no. 1, pages 1 - 7, XP002243972 DOI: http://dx.doi.org/10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.3.CO;2-R
		- BIOCCA et al., "Intracellular expression of anti- p21ras single chain Fv fragments inhibits meiotic maturation of xenopus oocytes", Biochemical and Biophysical Research Communications, (19931215), vol. 197, no. 2, pages 422 - 427, XP024766719 DOI: http://dx.doi.org/10.1006/bbrc.1993.2496
		- VALLE et al., "Anti-ovalbumin monoclonal antibodies interact with their antigen in internal membranes of Xenopus oocytes", Letters to Nature, (19821104), vol. 300, pages 71 - 74, XP055410643 DOI: http://dx.doi.org/10.1038/300071a0
		- BURKE et al., "Microinjections of mRNA coding for an Anti-Golgi Antibody inhibits intracellular transport of a Viral Membrane Protein", Cell, (19840400), vol. 36, no. 4, pages 847 - 856, XP027462338 DOI: http://dx.doi.org/10.1016/0092-8674(84)90034-5
		- ROSA et al., "An antibody against Secretogranin I (Chromogranin B) is packaged into secretory granules", The Journal of Cell Biology, (19890701), vol. 109, no. 1, pages 17 - 34, XP055410637 DOI: http://dx.doi.org/10.1083/jcb.109.1.17
		- RICHARDSON et al., "Intrabody-mediated knockout of the high-affinity IL 2 receptor in primary human T cells using a bicistronic lentivirus vector", Gene Therapy, (19980600), vol. 5, no. 5, pages 635 - 644, XP001026710 DOI: http://dx.doi.org/10.1038/sj.gt.3300644
		- CONRY et al., "Characterization of a Messenger RNA polynucleotide Vaccine Vector", Cancer Research, (19950401), vol. 55, no. 7, pages 1397 - 1400, XP000576177
		- KALLEN et al., "A novel, disruptive vaccination technology", Human Vaccines & Immunotherapeutics, (20131000), vol. 9, no. 10, pages 1 - 14, XP055126357 DOI: http://dx.doi.org/10.4161/hv.25181
		- WOLFF et al., "Direct gene transfer into mouse muscle in vivo", Science, (19900323), vol. 247, no. 4949, pages 1465 - 1468, XP000293057 DOI: http://dx.doi.org/10.1126/science.1690918
		- PARDI et al., "Expression kinetics of nucleoside- modified mRNA delivered in lipid nanoparticles to mice by various routes", J. Control Release, (20151110), vol. 217, pages 345 - 351, XP055231069 DOI: http://dx.doi.org/10.1016/j.jconrel.2015.08.007
		- MAYFIELD et al., "Expression and assembly of a fully active antibody in algae", Proc Natl Acad Sci, (20030000), vol. 100, no. 2, pages 438 - 442, XP002440629 DOI: http://dx.doi.org/10.1073/pnas.0237108100
		- LESAFFRE et al., "Direct non-cell autonomous Pax6 activity regulates eye development in the zebrafish", Neural Development, (20070000), vol. 2, no. 2, pages 1 - 12, XP021026216 DOI: http://dx.doi.org/10.1186/1749-8104-2-2
		- KITAGUCHI et al., "Immune deficiency enhances expression of recombinant humanantibody in mice after nonviral in vivo gene transfer", International Journal of Molecular Medicine, (20050000), vol. 16, no. 4, pages 683 - 688, XP008118466
		- PASCOLO et al., "Vaccination with messenger RNA", Methods in Molecular Medicine, (20060000), vol. 127, pages 23 - 40, XP009117840
		- HOERR INGMAR, "Stabilized messenger RNA (RNActive (TM)) as a tool for innovative gene delivery", 2ND INTERNATIONAL CONGRESS ON REGENERATIVE BIOLOGY/2ND INTERNATIONAL CONGRESS ON BIO-NANO-INTERFACE, (20070000), pages 886 - 887, XP009125215
		- HECKER et al., "681. Non-Viral DNA and mRNA Gene Delivery to the CNS Pre-Operatively for Neuroprotection and Following Neurotrauma", Molecular Therapy, (20040000), vol. 9, no. 1, doi:10.1016/j.ymthe.2004.06.570, page S258, XP055415696 DOI: http://dx.doi.org/10.1016/j.ymthe.2004.06.570
		- PROBST et al., "Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent", Gene Therapy, (20070000), vol. 14, doi:10.1038/SJ.GT.3302964, pages 1175 - 1180, XP002679377 DOI: http://dx.doi.org/10.1038/SJ.GT.3302964
		- KUDLA et al., "High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells", PLoS Biol, (20060000), vol. 4, no. 6, doi:10.1371/journal.pbio.0040180, pages 933 - 942, XP002484439 DOI: http://dx.doi.org/10.1371/journal.pbio.0040180
		- WEIDE et al., "Plasmid DNA- and messenger RNA-based anti-cancer vaccination", Immunology Letters, (20080000), vol. 115, pages 33 - 42, XP026863354
		- RAMMENSEE et al., "Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer", Immunology and Cell Biology, (20060000), vol. 84, pages 290 - 294, XP009092600 DOI: http://dx.doi.org/10.1111/j.1440-1711.2006.01442.x
		- VALLE et al., "Synthesis and secretion of mouse immunoglobulin chains from Xenopus oocytes", Nature, (19810000), vol. 291, pages 338 - 340, XP002764726
	- VALLE et al., "Anti-ovalbumin monoclonal antibodies interact with their antigen in internal membranes of Xenopus oocytes", Nature, (19820000), vol. 300, pages 71 - 74, XP055410643 DOI: http://dx.doi.org/10.1038/300071a0
	- DEACON et al., "Post-translational modification of rat immunoglobulins synthesized in the Xenopus oocyte translation system", Immunology, (19790000), vol. 38, pages 137 - 144, XP055415711
	- RABINOVICH et al., "Synthetic messenger RNA as a tool for gene therapy", Human Gene Therapy, (20060000), vol. 17, pages 1027 - 1035, XP002489890 DOI: http://dx.doi.org/10.1089/hum.2006.17.1027
	- SEIDEN et al., "A Phase II Trial of EMD72000 (Matuzumab), a Humanized Anti-Egfr Monoclonal Antibody, in Patients With Platinum-Resistant Ovarian and Primary Peritoneal Malignancies", Gynecol Oncol, (20070000), vol. 104, no. 3, pages 727 - 731, XP005894047 DOI: http://dx.doi.org/10.1016/j.ygyno.2006.10.019
	- KOLB et al., "Expression of a Recombinant Monoclonal Antibody From a Bicistronic mRNA", Hybridoma, (19970000), vol. 16, no. 5, pages 421 - 426, XP009006485
	- NOEL et al., "High In Vivo Production of a Model Monoclonal Antibody on Adenoviral Gene Transfer INTRODUCTION", Human Gene Therapy, (20020000), vol. 13, pages 1483 - 1493, XP008112130 DOI: http://dx.doi.org/10.1089/10430340260185111
	- PELLEGRIN et al., "Monoclonal Antibody-based Genetic Immunotherapy", Current Gene Therapy, (20040000), vol. 4, no. 3, pages 347 - 356, XP009048364
	- TJELLE et al., "Monoclonal Antibodies Produced by Muscle after Plasmid Injection and Electroporation", Mol Therapy, (20040000), vol. 9, no. 3, pages 328 - 336, XP055415724 DOI: http://dx.doi.org/10.1016/j.ymthe.2003.12.007
	- JIANG et al., "Gene Therapy Using Adenovirus-Mediated Full-length Anti-HER-2 Antibody for HER-2 Overexpression Cancers", Clin Cancer Res, (20060000), vol. 12, no. 20, pages 6179 - 6185, XP055167239 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-06-0746
	- FANG et al., "Stable antibody expression at therapeutic levels using the 2A peptide", Nature Biotechnology, (20050000), vol. 23, no. 5, doi:10.1038/NBT1087, pages 584 - 590, XP002546320 DOI: http://dx.doi.org/10.1038/NBT1087
	- MIELKE et al., "Stabilized, long-term expression of heterodimeric proteins from tricistronic mRNA", Gene, (20000000), vol. 254, pages 1 - 8, XP004208775 DOI: http://dx.doi.org/10.1016/S0378-1119(00)00294-8
	- WEIDE et al., "Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.", J Immunother, (20080000), vol. 31, no. 2, pages 180 - 188, XP009125242 DOI: http://dx.doi.org/10.1097/CJI.0b013e31815ce501
	- HOERR et al., "In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies.", Eur J Immunol, (20000000), vol. 30, pages 1 - 7, XP002243972 DOI: http://dx.doi.org/10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.3.CO;2-R
	- "Dictionary definition of mRNA", Dr. A.D. Smith, Oxford Dictionary of Biochemistry and Molecular Biology, (20000000), page 407, ISBN 0198506732, XP055415734
	- "Dictionary definition of antibody", Dr. A.D. Smith, Oxford Dictionary of Biochemistry and Molecular Biology, (20000000), page 42, XP055415736
	- LIN et al., "A Phase I/Ii Dose Escalation Study of Apolizumab (Hu1D10) Using a Stepped-Up Dosing Schedule in Patients With Chronic Lymphocytic Leukemia and Acute Leukemia", Leuk Lymphoma, (20090000), vol. 50, no. 12, pages 1958 - 1963, XP055415743 DOI: http://dx.doi.org/10.3109/10428190903186486
	- WOLFF et al., "Direct gene transfer into mouse muscle in vivo", Science, (19900000), vol. 247, no. 4949, pages 1465 - 1468, XP000293057 DOI: http://dx.doi.org/10.1126/science.1690918
	- SOREQ et al., "The biosynthesis of biologically active proteins in mRNA-microinjected Xenopus oocytes.", Critical Reviews in Biochemistry, (19850000), vol. 18, no. 3, pages 199 - 238, XP055415747
	- "Dictionary definition of immunoglobulin", Oxford Dictionary of Biochemistry and Molecular Biology, (20000000), pages 326 - 327, ISBN 0198506732, XP055416032
	- "Rituxan product information", IDEC Pharmaceuticals Corporation, (20040600), XP055416036
	- LEGET et al., "Use of rituximab, the new FDA-approved antibody", Current Opinion in Oncology, (19980000), vol. 10, pages 548 - 551, XP000952702
	- REFF et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20", Blood, (19940000), vol. 83, no. 2, pages 435 - 445, XP002112549
	- KHARE et al., "Tumor growth suppression by a retroviral vector displaying scFv antibody to CEA and carrying the iNOS gene.", Anticancer Research, (20020000), vol. 22, no. 4, pages 2443 - 2446, XP008054734
	- BALENGA et al., "Bicistronic expression plasmid encoding allergen and anti-IgE single chain variable fragment antibody as a novel DNA vaccine for allergy therapy and prevention", Medical Hypotheses, (20060000), vol. 67, no. 1, pages 71 - 74, XP005397016 DOI: http://dx.doi.org/10.1016/j.mehy.2005.12.044
	- FINGER et al., "Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells", Cancer Gene Therapy, (20050000), vol. 12, pages 464 - 474, XP055039486 DOI: http://dx.doi.org/10.1038/sj.cgt.7700805
	- ALBRECHT et al., "Update : Recombinant Antibodies: From the Laboratory to the Clinic", Cancer Biotherapy & Radiopharm, (20060000), vol. 21, no. 4, pages 285 - 304, XP055416071 DOI: http://dx.doi.org/10.1089/cbr.2006.21.285
	- MUKHERJEE et al., "Prolonged Prophylactic Protection from Botulism with a Single Adenovirus Treatment Promoting Serum Expression of a VHH-Based Antitoxin Protein", Plos One, (20140000), vol. 9, no. 8, pages 1 - 13, XP055416073 DOI: http://dx.doi.org/10.1371/journal.pone.0106422
	- MAKEYEV et al., "The poly(C)-binding proteins: A multiplicity of functions and a search for mechanisms", RNA, (20020000), vol. 8, pages 265 - 278, XP055415495 DOI: http://dx.doi.org/10.1017/S1355838202024627
	- LEVENE et al., "Therapeutic monoclonal antibodies in oncology", Journal of the Royal Society of Medicine, (20050000), vol. 98, pages 146 - 152, XP055415498 DOI: http://dx.doi.org/10.1258/jrsm.98.4.146
	- LEWIS et al., "Generation of Neutralizing Activity against Human Immunodeficiency Virus Type I in Serum by Antibody Gene Transfer", Journal of Virology, (20020000), vol. 76, pages 8769 - 8775, XP002992256 DOI: http://dx.doi.org/10.1128/JVI.76.17.8769-8775.2002
	- KITAGUCHI et al., "Immune deficiency enhances expression of recombinant human antibody in mice after nonviral in vivo gene transfer", International Journal of Molecular Medicine, (20050000), vol. 16, pages 683 - 688, XP008118466
	- BAKKER et al., "Therapeutic Antibody Gene Transfer: An Active Approach to Passive Immunity", Molecular Therapy, (20040000), vol. 10, pages 411 - 416, XP004660582 DOI: http://dx.doi.org/10.1016/j.ymthe.2004.06.865
	- PASCOLO, "Vaccination with Messenger RNA", Methods in Molecular Medicine, (20060000), vol. 127, pages 23 - 40, XP009117840
	- HOERR, "Stabilized Messenger RNA (RNActive?) as a Tool for Innovative Gene Delivery", BioStar 2006 2nd International Congress on Regenerative Biology and ICBN 2006 2nd International Congress on Bio-Nano-Interface, vol. 13, (20060000), pages 886 - 887, (20070400), XP009125215
	- MARTINON et al., "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA", European Journal of Immunology, (19930000), vol. 23, pages 1719 - 1722, XP002937540 DOI: http://dx.doi.org/10.1002/eji.1830230749
	- J OHANNING et al., "A sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo", Nucleic Acids Research, (19950000), vol. 23, pages 1495 - 1501, XP002021791
	- BURKE et al., "Microinjection of mRNA Coding for an Anti-Golgi Antibody Inhibits Intracellular Transport of a Viral Membrane Protein", Cell, (19840000), vol. 36, pages 847 - 856, XP027462338 DOI: http://dx.doi.org/10.1016/0092-8674(84)90034-5
	- GREBER et al., "Nuclear Protein Import is Inhibited by an Antibody to a Luminal Epitope of a Nuclear Pore Complex Glycoprotein", The Journal of Cell Biology, (19920000), vol. 116, pages 15 - 30, XP055415543 DOI: http://dx.doi.org/10.1083/jcb.116.1.15
	- FLEETON et al., "Self-Replicative RNA Vaccines Elicit Protection against Influenza A Virus, Respiratory Syncytial Virus, and a Tickborne Encephalitis Virus", Journal of Infectious Diseases, (20010000), vol. 183, pages 1395 - 1398, XP055089099 DOI: http://dx.doi.org/10.1086/319857
	- "RNA-based Therapies", PASCOLO, Drug Discovery Handbook, Hoboken, NJ, (20050000), pages 1259 - 1300, XP055415554 DOI: http://dx.doi.org/10.1002/0471728780.ch27
	- KOLB et al., "A virus-neutralising antibody is not cytotoxic in vitro", Mol Immunol, (20060000), vol. 43, pages 677 - 689, XP027899258
	- HESS et al., "Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen", Cancer Immunol Immunother., (20060000), vol. 55, no. 6, pages 672 - 683, XP019333249 DOI: http://dx.doi.org/10.1007/s00262-005-0064-z
	- CARRALOT et al., "Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines", Cell Mol Life Sci., (20040000), vol. 61, no. 18, pages 2418 - 2424, XP002355208 DOI: http://dx.doi.org/10.1007/s00018-004-4255-0
	- HOERR, "Stabilized Messenger RNA (RNActive?) as a Tool for Innovative Gene Delivery", Tissue Eng., (20070000), vol. 13, no. 4, pages 886 - 887, XP009125215
	- PROBST et al., "Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific , saturable and ion dependent", Gene Ther., (20070000), vol. 14, no. 15, pages 1175 - 1180, XP002679377 DOI: http://dx.doi.org/10.1038/SJ.GT.3302964
	- BHATTACHARYA-CHATTERJEE et al., "Counterpoint. Cancer vaccines: single- epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine", Cancer Immunol. Immunother., (20000000), vol. 49, no. 3, pages 133 - 141, XP001010379 DOI: http://dx.doi.org/10.1007/s002620050612
	- LUTZKY et al., "Antibody-based vaccines for the treatment of melanoma", Seminars in Oncology, (20020000), vol. 29, no. 5, pages 462 - 470, XP055415562 DOI: http://dx.doi.org/10.1053/sonc.2002.35241
	- IVANOVSKA et al., "Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD 21-specific antibody fragment induces long- lasting IgM and CTL responses to influenza virus", Vaccine, (20060000), vol. 24, no. 11, pages 1830 - 1837, XP028011227 DOI: http://dx.doi.org/10.1016/j.vaccine.2005.10.029
	- ZEYTIN et al., "Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1a7 mimicking the tumor-associated antigen disialoganglioside GD2", Cancer Gene Therapy, (20000000), vol. 7, no. 11, pages 1426 - 1436, XP001145646 DOI: http://dx.doi.org/10.1038/sj.cgt.7700240
	- BAKKER et al., "Therapeutic Antibody Gene Transfer: An Active Approach to Passive Immunity", Mol Ther., (20040000), vol. 10, no. 3, pages 411 - 416, XP004660582 DOI: http://dx.doi.org/10.1016/j.ymthe.2004.06.865
	- KITAGUCHI et al., "Immune deficiency enhances expression of recombinant human antibody in mice after non-viral in vivo gene transfer", Int J Mol Med., (20050000), vol. 4, pages 683 - 688, XP008118466
	- BURKE et al., "Microinjections of mRNA Coding for an Anti-Golgi Antibody Inhibits Intracellular Transport of a Viral Membrane Protein", Cell, (19840000), vol. 36, pages 847 - 856, XP027462338 DOI: http://dx.doi.org/10.1016/0092-8674(84)90034-5
	- ROSA et al., "An Antibody Against Secretogranin I (Chromogranin B) is Packaged into Secretory Granules", J Cell Biol., (19890000), vol. 109, pages 17 - 34, XP055410637 DOI: http://dx.doi.org/10.1083/jcb.109.1.17
	- THESS et al., "Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals", Am Soc Gene Cell Ther., (20150000), vol. 23, no. 9, pages 1456 - 1464, XP055316910 DOI: http://dx.doi.org/10.1038/mt.2015.103
	- MIZUGUCHI et al., "IRES-Dependent Second Gene Expression is Significantly Lower Than Cap-Dependent First Gene Expression in a Bicistronic s Vector", Mol Ther, (20000000), vol. 1, no. 4, pages 376 - 382, XP002213078 DOI: http://dx.doi.org/10.1006/mthe.2000.0050
	- HOTTA et al., "Production of Anti-CD 2 Chimeric Antibody by Recombinant Animal Cells", J Biosci Bioeng, (20040000), vol. 98, no. 4, pages 298 - 303, XP004649520
	- YOUN et al., "Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy", Expert Opin Biol Ther., (20150000), vol. 15, no. 9, pages 1337 - 1348, XP055406240 DOI: http://dx.doi.org/10.1517/14712598.2015.1057563
	- HU et al., "Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris", Protein Expr Purif., (20060500), vol. 47, no. 1, pages 249 - 257, XP024908737 DOI: http://dx.doi.org/10.1016/j.pep.2005.11.014
	- MAYFIELD et al., "Expression and assembly of a fully active antibody in algae", PNAS, (20030100), vol. 100, no. 2, pages 438 - 442, XP002440629 DOI: http://dx.doi.org/10.1073/pnas.0237108100
	- KHARE et al., "TUMOR GROWTH SUPPRESSION BY A RETROVIRAL VECTOR DISPLAYING SCFV ANTIBODY TO CEA AND CARRYING THE INOS GENE", Anticancer Res., (20020100), vol. 22, pages 2443 - 6, XP008054734
	- OHASHI et al., "Efficient protein selection based on ribosome display system with purified components", Biochem Biophys Res Commun, (20061100), vol. 352, no. 1, pages 270 - 6, XP005724593 DOI: http://dx.doi.org/10.1016/j.bbrc.2006.11.017
	- IVANOVSKA et al., "Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD21-specific antibody fragment induces long-lasting IgM and CTL responses to influenza virus", Vaccine, (20060300), vol. 24, no. 11, pages 1830 - 7, XP028011227 DOI: http://dx.doi.org/10.1016/j.vaccine.2005.10.029
	- CARRALOT et al., "Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines", Cell Mol Life Sci., (20040900), vol. 61, no. 18, pages 2418 - 24, XP002355208 DOI: http://dx.doi.org/10.1007/s00018-004-4255-0
	- CREE et al., "Tolerability and effects of Rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS)", Neurology, (20040400), vol. 62, no. 5, page A492, XP009080814
	- BAKKER et al., "Therapeutic Antibody Gene Transfer: An Active Approach to Passive Immunity", Mol Ther., (20040900), vol. 10, no. 3, pages 411 - 6, XP004660582 DOI: http://dx.doi.org/10.1016/j.ymthe.2004.06.865
	- KOLB et al., "A virus-neutralising antibody is not cytotoxic in vitro", Mol Immunol., (20060200), vol. 43, no. 6, pages 677 - 89, XP027899258
	- FUKUDA et al., "In vitro evolution of single-chain antibodies using mRNA display", Nucleic Acids Res., (20060900), vol. 34, no. 19, page E127, XP002639193 DOI: http://dx.doi.org/10.1093/NAR/GKL618
	- LESAFFRE et al., "Direct non-cell autonomous Pax6 activity regulates eye development in the zebrafish", Neural Dev., (20070100), vol. 2, page 2, XP021026216 DOI: http://dx.doi.org/10.1186/1749-8104-2-2
	- ZEYTIN et al., "CONSTRUCTION AND CHARACTERIZATION OF DNA VACCINES ENCODING THE SINGLE-CHAIN VARIABLE FRAGMENT OF THE ANTI-IDIOTYPE ANTIBODY 1A7 MIMICKING THE TUMOR-ASSOCIATED ANTIGEN DISIALOGANGLIOSIDE GD2", Cancer Gene Ther., (20001100), vol. 7, no. 11, pages 1426 - 36, XP001145646 DOI: http://dx.doi.org/10.1038/sj.cgt.7700240
	- BANDBON et al., "Bicistronic expression plasmid encoding allergen and anti-IgE single chain variable fragment antibody as a novel DNA vaccine for allergy therapy and prevention", Med Hypotheses., (20060100), vol. 67, no. 1, pages 71 - 4, XP005397016 DOI: http://dx.doi.org/10.1016/j.mehy.2005.12.044
	- KITAGUCHI et al., "Immune deficiency enhances expression of recombinant human antibody in mice after nonviral in vivo gene transfer", Int J Mol Med., (20051000), vol. 16, no. 4, pages 683 - 8, XP008118466
	- PASCOLO, "Vaccination With Messenger RNA", Methods Mol Med., (20060000), vol. 127, pages 23 - 40, XP009117840
	- HOERR, "Stabilized messenger RNA (RNActive (TM)) as a tool for innovative gene delivery", Tissue Eng., (20070400), vol. 13, no. 4, pages 886 - 7, XP009125215
	- HECKER et al., "Non-Viral DNA and mRNA Gene Delivery to the CNS Pre-Operatively for Neuroprotection and Following Neurotrauma", Mol Ther., (20040500), vol. 9, no. 1, page 258, XP055415696 DOI: http://dx.doi.org/10.1016/j.ymthe.2004.06.570
	- FINGER et al., "Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.", Cancer Gene Ther., (20050000), vol. 12, no. 5, pages 464 - 474, XP055039486 DOI: http://dx.doi.org/10.1038/sj.cgt.7700805
	- HESS et al., "Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.", Cancer Immunol Immunother, (20060600), vol. 55, no. 6, pages 1432 - 0851, XP019333249 DOI: http://dx.doi.org/10.1007/s00262-005-0064-z
	- PROBST et al., "Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent", Gene Ther., (20070800), vol. 14, no. 15, pages 1175 - 80, XP002679377 DOI: http://dx.doi.org/10.1038/SJ.GT.3302964
	- FANG et al., "Stable antibody expression at therapeutic levels using the 2A peptide", Nature Biotechnol., (20050500), vol. 23, no. 5, pages 584 - 90, XP002369310 DOI: http://dx.doi.org/10.1038/nbt1087
	- KARIKÔ et al., "Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA", Immunity, (20050800), vol. 23, no. 2, pages 165 - 75, XP002634064 DOI: http://dx.doi.org/10.1016/J.IMMUNI.2005.06.008
	- HOERR et al., "In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies", Eur J Immunol., (20000100), vol. 30, no. 1, pages 1 - 7, XP002243972 DOI: http://dx.doi.org/10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.3.CO;2-R
	- BELIZÀRIO, "immunodeficient mouse models: an overview", Open Immunol J., (20090000), vol. 2, pages 72 - 85, XP055417412 DOI: http://dx.doi.org/10.2174/1874226200902010079
	- ITO et al., "NOD/SCID/GAMMAcnull mouse: an excellent recipient mouse model for engraftment of human cells", Blood, (20021100), vol. 100, no. 9, pages 3175 - 82, XP002981771 DOI: http://dx.doi.org/10.1182/blood-2001-12-0207
	- TAMURA et al., "CELLULAR AND HUMORAL IMMUNE RESPONSES IN MICE I. DEVELOPMENT OF DELAYED-TYPE FOOTPAD SWELLING AGAINST SHEEP ERYTHROCYTES AND ITS SUPPRESSION BY INTRAPERITONEAL ADMINISTRATION OF THE ANTIGEN", J. Med. Sci. Biol., (19730000), vol. 26, pages 161 - 168, XP055417418
	- Frequently Asked Questions page from SignalP website
	- Cox et al., "Chapter 7.2. Plasmid DNA and Messenger RNA for Therapy", Cox et al., Cox et al., Handbook of Pharmaceutical Biotechnology, (20060824), pages 971 - 1011, XP055626043 DOI: http://dx.doi.org/10.1002/9780470117118.ch07b
	- ROSA et al., "An antibody against secretogranin I (chromogranin B) is packaged into secretory granules", The Journal of Cell Biology, (19890701), vol. 109, no. 1, pages 17 - 34, XP055410637 DOI: http://dx.doi.org/10.1083/jcb.109.1.17

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p